HRP20100408T1 - DERIVATI 2-ARIL-6-FENILIMIDAZO[1,2-a]PIRIDINA, NJIHOVO DOBIVANJE I UPOTREBA U TERAPIJI - Google Patents
DERIVATI 2-ARIL-6-FENILIMIDAZO[1,2-a]PIRIDINA, NJIHOVO DOBIVANJE I UPOTREBA U TERAPIJI Download PDFInfo
- Publication number
- HRP20100408T1 HRP20100408T1 HR20100408T HRP20100408T HRP20100408T1 HR P20100408 T1 HRP20100408 T1 HR P20100408T1 HR 20100408 T HR20100408 T HR 20100408T HR P20100408 T HRP20100408 T HR P20100408T HR P20100408 T1 HRP20100408 T1 HR P20100408T1
- Authority
- HR
- Croatia
- Prior art keywords
- cycloalkyl
- alkyl
- phenyl
- pyridin
- imidazo
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims 9
- 230000001225 therapeutic effect Effects 0.000 title 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims abstract 85
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 72
- 229910052736 halogen Inorganic materials 0.000 claims abstract 55
- 125000003118 aryl group Chemical group 0.000 claims abstract 47
- 150000002367 halogens Chemical class 0.000 claims abstract 44
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 42
- 150000001875 compounds Chemical class 0.000 claims abstract 35
- 125000002947 alkylene group Chemical group 0.000 claims abstract 33
- 229910003827 NRaRb Inorganic materials 0.000 claims abstract 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 24
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 23
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 20
- 125000001424 substituent group Chemical group 0.000 claims abstract 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 14
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims abstract 12
- 125000004429 atom Chemical group 0.000 claims abstract 10
- 125000005529 alkyleneoxy group Chemical group 0.000 claims abstract 8
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 6
- 125000001624 naphthyl group Chemical group 0.000 claims abstract 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims abstract 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims abstract 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 4
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical group C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims abstract 2
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims abstract 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 2
- 125000004001 thioalkyl group Chemical group 0.000 claims abstract 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000005843 halogen group Chemical group 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 11
- 239000002253 acid Substances 0.000 claims 10
- 229940079593 drug Drugs 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 7
- -1 (C3-C7)CycloAlkoxy Chemical group 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 125000006557 (C2-C5) alkylene group Chemical group 0.000 claims 2
- MYONEJYVJVQVAF-UHFFFAOYSA-N 1-[3-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC(C2=CN3C=C(N=C3C=C2)C=2C=CC(Cl)=CC=2)=C1 MYONEJYVJVQVAF-UHFFFAOYSA-N 0.000 claims 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical group [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 2
- 238000006482 condensation reaction Methods 0.000 claims 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- PDCSZSDAIIGGJS-UHFFFAOYSA-N 1-[3-[2-(2,4-difluorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC(C2=CN3C=C(N=C3C=C2)C=2C(=CC(F)=CC=2)F)=C1 PDCSZSDAIIGGJS-UHFFFAOYSA-N 0.000 claims 1
- YSCIMARAKJTOQO-UHFFFAOYSA-N 1-[3-[2-(2-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC(C2=CN3C=C(N=C3C=C2)C=2C(=CC=CC=2)Cl)=C1 YSCIMARAKJTOQO-UHFFFAOYSA-N 0.000 claims 1
- VAQRCUNRDMEKOK-UHFFFAOYSA-N 1-[3-[2-(3,4-difluorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC(C2=CN3C=C(N=C3C=C2)C=2C=C(F)C(F)=CC=2)=C1 VAQRCUNRDMEKOK-UHFFFAOYSA-N 0.000 claims 1
- ZSUXFNRFDYZPEB-UHFFFAOYSA-N 1-[3-[2-(3-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]ethanol 4-[6-[3-(hydroxymethyl)phenyl]imidazo[1,2-a]pyridin-2-yl]phenol Chemical compound OCC=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C2=CC=C(C=C2)O.ClC=2C=C(C=CC2)C=2N=C1N(C=C(C=C1)C=1C=C(C=CC1)C(C)O)C2 ZSUXFNRFDYZPEB-UHFFFAOYSA-N 0.000 claims 1
- SOLQRLFTNWMKLR-UHFFFAOYSA-N 1-[3-[2-(3-fluorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC(C2=CN3C=C(N=C3C=C2)C=2C=C(F)C=CC=2)=C1 SOLQRLFTNWMKLR-UHFFFAOYSA-N 0.000 claims 1
- UBTSBKDDTUQXRU-UHFFFAOYSA-N 1-[3-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]-3-methylbutan-1-ol Chemical compound CC(C)CC(O)C1=CC=CC(C2=CN3C=C(N=C3C=C2)C=2C=CC(Cl)=CC=2)=C1 UBTSBKDDTUQXRU-UHFFFAOYSA-N 0.000 claims 1
- JZTXDXUREYZCFA-UHFFFAOYSA-N 1-[3-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]heptan-1-ol Chemical compound CCCCCCC(O)C1=CC=CC(C2=CN3C=C(N=C3C=C2)C=2C=CC(Cl)=CC=2)=C1 JZTXDXUREYZCFA-UHFFFAOYSA-N 0.000 claims 1
- LGZVZMDOBADMFD-UHFFFAOYSA-N 1-[3-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]pentan-1-ol Chemical compound CCCCC(O)C1=CC=CC(C2=CN3C=C(N=C3C=C2)C=2C=CC(Cl)=CC=2)=C1 LGZVZMDOBADMFD-UHFFFAOYSA-N 0.000 claims 1
- PCLPUMSFIGAPDD-UHFFFAOYSA-N 1-[3-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]propan-1-ol Chemical compound CCC(O)C1=CC=CC(C2=CN3C=C(N=C3C=C2)C=2C=CC(Cl)=CC=2)=C1 PCLPUMSFIGAPDD-UHFFFAOYSA-N 0.000 claims 1
- JTTPDWXPTGRTJI-UHFFFAOYSA-N 1-[3-[2-(4-fluorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC(C2=CN3C=C(N=C3C=C2)C=2C=CC(F)=CC=2)=C1 JTTPDWXPTGRTJI-UHFFFAOYSA-N 0.000 claims 1
- NFXJURRZLLYBPN-UHFFFAOYSA-N 1-[4-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]ethanol Chemical compound C1=CC(C(O)C)=CC=C1C1=CN2C=C(C=3C=CC(Cl)=CC=3)N=C2C=C1 NFXJURRZLLYBPN-UHFFFAOYSA-N 0.000 claims 1
- ZYANTTOKFDWNGJ-UHFFFAOYSA-N 1-[4-[[3-[2-(4-methylphenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]methoxy]phenyl]ethanone 2-(4-methylphenyl)-6-[3-[[4-(trifluoromethyl)phenoxy]methyl]phenyl]imidazo[1,2-a]pyridine Chemical compound FC(C1=CC=C(OCC=2C=C(C=CC2)C=2C=CC=3N(C2)C=C(N3)C3=CC=C(C=C3)C)C=C1)(F)F.C1(=CC=C(C=C1)C=1N=C3N(C=C(C=C3)C=3C=C(COC2=CC=C(C=C2)C(C)=O)C=CC3)C1)C ZYANTTOKFDWNGJ-UHFFFAOYSA-N 0.000 claims 1
- HYURVCUMJWEFMW-UHFFFAOYSA-N 2-(4-chlorophenyl)-6-[2-(methoxymethyl)phenyl]imidazo[1,2-a]pyridine;hydrochloride Chemical compound Cl.COCC1=CC=CC=C1C1=CN2C=C(C=3C=CC(Cl)=CC=3)N=C2C=C1 HYURVCUMJWEFMW-UHFFFAOYSA-N 0.000 claims 1
- OBWVJVVNWMBROP-UHFFFAOYSA-N 2-(4-chlorophenyl)-6-[4-(methoxymethyl)phenyl]imidazo[1,2-a]pyridine Chemical compound C1=CC(COC)=CC=C1C1=CN2C=C(C=3C=CC(Cl)=CC=3)N=C2C=C1 OBWVJVVNWMBROP-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- QLTFWCTVWLJGQX-UHFFFAOYSA-N C1(=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(COC3=CC=C(C#N)C=C3)C=CC2)C1)C.CC1=CC=C(OCC=2C=C(C=CC2)C=2C=CC=3N(C2)C=C(N3)C3=CC=C(C=C3)C)C=C1.[N+](=O)([O-])C=1C=C(OCC=3C=C(C=CC3)C=3C=CC=2N(C3)C=C(N2)C2=CC=C(C=C2)C)C=CC1 Chemical compound C1(=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(COC3=CC=C(C#N)C=C3)C=CC2)C1)C.CC1=CC=C(OCC=2C=C(C=CC2)C=2C=CC=3N(C2)C=C(N3)C3=CC=C(C=C3)C)C=C1.[N+](=O)([O-])C=1C=C(OCC=3C=C(C=CC3)C=3C=CC=2N(C3)C=C(N2)C2=CC=C(C=C2)C)C=CC1 QLTFWCTVWLJGQX-UHFFFAOYSA-N 0.000 claims 1
- VZMAEKSHJBIDKO-UHFFFAOYSA-N C1(=CC=CC2=CC=CC=C12)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.C(C)N(C1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=CC=C(C=C2)CO)C1)CC Chemical compound C1(=CC=CC2=CC=CC=C12)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.C(C)N(C1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=CC=C(C=C2)CO)C1)CC VZMAEKSHJBIDKO-UHFFFAOYSA-N 0.000 claims 1
- QUXHWCXYIKKQDS-UHFFFAOYSA-N COC1=C(C=CC=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.COC=1C=C(C=CC1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.COC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 Chemical compound COC1=C(C=CC=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.COC=1C=C(C=CC1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.COC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 QUXHWCXYIKKQDS-UHFFFAOYSA-N 0.000 claims 1
- QZZBPRCKWNYDOY-UHFFFAOYSA-N COCCOCC=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C2=CC1=CC=CC=C1C=C2.CC2=C(C=CC(=C2)C)C=2N=C1N(C=C(C=C1)C=1C=C(C=CC1)CO)C2 Chemical compound COCCOCC=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C2=CC1=CC=CC=C1C=C2.CC2=C(C=CC(=C2)C)C=2N=C1N(C=C(C=C1)C=1C=C(C=CC1)CO)C2 QZZBPRCKWNYDOY-UHFFFAOYSA-N 0.000 claims 1
- PRSURGCTCWKNQS-UHFFFAOYSA-N Cc1ccc(cc1)-c1cn2cc(ccc2n1)-c1cccc(COc2ccc(Cl)cc2)c1.CC(=O)Nc1ccc(OCc2cccc(c2)-c2ccc3nc(cn3c2)-c2ccc(C)cc2)cc1 Chemical compound Cc1ccc(cc1)-c1cn2cc(ccc2n1)-c1cccc(COc2ccc(Cl)cc2)c1.CC(=O)Nc1ccc(OCc2cccc(c2)-c2ccc3nc(cn3c2)-c2ccc(C)cc2)cc1 PRSURGCTCWKNQS-UHFFFAOYSA-N 0.000 claims 1
- STGKULPTJBQCKB-UHFFFAOYSA-N Cl.ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=C(C=CC=C2)CO)C1.ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=C(C=CC=C2)CO)C1 Chemical compound Cl.ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=C(C=CC=C2)CO)C1.ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=C(C=CC=C2)CO)C1 STGKULPTJBQCKB-UHFFFAOYSA-N 0.000 claims 1
- CHLWMYLAYHUWKV-UHFFFAOYSA-N Cl.ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 Chemical compound Cl.ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 CHLWMYLAYHUWKV-UHFFFAOYSA-N 0.000 claims 1
- XISBGQXCHIJQBU-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1)C.ClC=1C=C(C=CC1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 Chemical compound ClC1=C(C=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1)C.ClC=1C=C(C=CC1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 XISBGQXCHIJQBU-UHFFFAOYSA-N 0.000 claims 1
- DCDKUYUYSWGOPX-UHFFFAOYSA-N ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=C(C=CC=C2)COC)C1.ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=C(C=CC=C2)C(C)O)C1 Chemical compound ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=C(C=CC=C2)COC)C1.ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=C(C=CC=C2)C(C)O)C1 DCDKUYUYSWGOPX-UHFFFAOYSA-N 0.000 claims 1
- YBHUYJLFUBUVPZ-UHFFFAOYSA-N ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=CC(=CC=C2)COC)C1.ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)C(C)O)C1 Chemical compound ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=CC(=CC=C2)COC)C1.ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)C(C)O)C1 YBHUYJLFUBUVPZ-UHFFFAOYSA-N 0.000 claims 1
- NHPDCHQXQGOMHW-UHFFFAOYSA-N ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)C(C)(C)O)C1.FC=1C=C(C=CC1C)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 Chemical compound ClC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)C(C)(C)O)C1.FC=1C=C(C=CC1C)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 NHPDCHQXQGOMHW-UHFFFAOYSA-N 0.000 claims 1
- VRGLPXBXHOEQCL-UHFFFAOYSA-N FC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.COC1=C(C=CC(=C1)OC)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 Chemical compound FC1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.COC1=C(C=CC(=C1)OC)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 VRGLPXBXHOEQCL-UHFFFAOYSA-N 0.000 claims 1
- CJPPQXQVGDELPM-UHFFFAOYSA-N FC=1C=C(C=CC1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.ClC=1C=C(C=CC1Cl)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 Chemical compound FC=1C=C(C=CC1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.ClC=1C=C(C=CC1Cl)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 CJPPQXQVGDELPM-UHFFFAOYSA-N 0.000 claims 1
- MPXXJIXCNWQVSU-UHFFFAOYSA-N FC=1C=C(C=CC1F)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.FC1=C(C=CC(=C1)F)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 Chemical compound FC=1C=C(C=CC1F)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.FC1=C(C=CC(=C1)F)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 MPXXJIXCNWQVSU-UHFFFAOYSA-N 0.000 claims 1
- UKXGHSHFJVVZHD-UHFFFAOYSA-N N1(CCCC1)C1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=CC=C(C=C2)CO)C1.C1(=CC=CC=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.C1(=CC=CC=C1)C=1N=C2N(C=C(C=C2)C2=CC=C(C=C2)CO)C1 Chemical compound N1(CCCC1)C1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=CC=C(C=C2)CO)C1.C1(=CC=CC=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.C1(=CC=CC=C1)C=1N=C2N(C=C(C=C2)C2=CC=C(C=C2)CO)C1 UKXGHSHFJVVZHD-UHFFFAOYSA-N 0.000 claims 1
- RJMBORZGZOBATF-UHFFFAOYSA-N N1(CCCC1)C1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.C1(=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1)C.C1=C(C=CC2=CC=CC=C12)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 Chemical compound N1(CCCC1)C1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.C1(=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1)C.C1=C(C=CC2=CC=CC=C12)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 RJMBORZGZOBATF-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- DLOYTHNNVWMZAD-UHFFFAOYSA-N OCC=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C2=CC=C(C#N)C=C2.COCCOCC=2C=C(C=CC2)C=2C=CC=1N(C2)C=C(N1)C=1C=C(C#N)C=CC1 Chemical compound OCC=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C2=CC=C(C#N)C=C2.COCCOCC=2C=C(C=CC2)C=2C=CC=1N(C2)C=C(N1)C=1C=C(C#N)C=CC1 DLOYTHNNVWMZAD-UHFFFAOYSA-N 0.000 claims 1
- OKOGJTHOFMPIHZ-UHFFFAOYSA-N OCC=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C=2C=C(C#N)C=CC2.OCC2=CC=C(C=C2)C=2C=CC=1N(C2)C=C(N1)C=1C=C(C#N)C=CC1.C1(=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=CC=C(C=C2)CO)C1)C1=CC=CC=C1 Chemical compound OCC=1C=C(C=CC1)C=1C=CC=2N(C1)C=C(N2)C=2C=C(C#N)C=CC2.OCC2=CC=C(C=C2)C=2C=CC=1N(C2)C=C(N1)C=1C=C(C#N)C=CC1.C1(=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C2=CC=C(C=C2)CO)C1)C1=CC=CC=C1 OKOGJTHOFMPIHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000034799 Tauopathies Diseases 0.000 claims 1
- HOTODYIWLPMBRK-UHFFFAOYSA-N [3-[2-(2-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]methanol [3-[2-[4-(trifluoromethyl)phenyl]imidazo[1,2-a]pyridin-6-yl]phenyl]methanol Chemical compound FC(C1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1)(F)F.ClC1=C(C=CC=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1 HOTODYIWLPMBRK-UHFFFAOYSA-N 0.000 claims 1
- XVDHAJOPZBKJTP-UHFFFAOYSA-N [3-[2-(3,4-difluorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]methanol;hydrochloride Chemical compound Cl.OCC1=CC=CC(C2=CN3C=C(N=C3C=C2)C=2C=C(F)C(F)=CC=2)=C1 XVDHAJOPZBKJTP-UHFFFAOYSA-N 0.000 claims 1
- LJPGFWXYBPREBX-UHFFFAOYSA-N [3-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]-cyclopentylmethanol Chemical compound C=1C=CC(C2=CN3C=C(N=C3C=C2)C=2C=CC(Cl)=CC=2)=CC=1C(O)C1CCCC1 LJPGFWXYBPREBX-UHFFFAOYSA-N 0.000 claims 1
- FLRVREFLPLXHCL-UHFFFAOYSA-N [3-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]-phenylmethanol Chemical compound C=1C=CC(C2=CN3C=C(N=C3C=C2)C=2C=CC(Cl)=CC=2)=CC=1C(O)C1=CC=CC=C1 FLRVREFLPLXHCL-UHFFFAOYSA-N 0.000 claims 1
- FMDRXVFYGAJKFK-UHFFFAOYSA-N [3-[2-[4-(difluoromethyl)phenyl]imidazo[1,2-a]pyridin-6-yl]phenyl]methanol Chemical compound OCC1=CC=CC(C2=CN3C=C(N=C3C=C2)C=2C=CC(=CC=2)C(F)F)=C1 FMDRXVFYGAJKFK-UHFFFAOYSA-N 0.000 claims 1
- DKKXSGSGLOGHSR-UHFFFAOYSA-N [N+](=O)([O-])C1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.FC(OC=1C=C(C=CC1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1)(F)F Chemical compound [N+](=O)([O-])C1=CC=C(C=C1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1.FC(OC=1C=C(C=CC1)C=1N=C2N(C=C(C=C2)C=2C=C(C=CC2)CO)C1)(F)F DKKXSGSGLOGHSR-UHFFFAOYSA-N 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 229910052987 metal hydride Inorganic materials 0.000 claims 1
- 150000004681 metal hydrides Chemical class 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000002524 organometallic group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Transplantation (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0608350A FR2906250B1 (fr) | 2006-09-22 | 2006-09-22 | Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique |
| PCT/FR2007/001517 WO2008034974A1 (fr) | 2006-09-22 | 2007-09-19 | DERIVES DE 2-ARYL-6-PHENYL-IMIDAZO[1,2-α]PYRIDINES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100408T1 true HRP20100408T1 (hr) | 2010-09-30 |
Family
ID=37841968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100408T HRP20100408T1 (hr) | 2006-09-22 | 2010-07-23 | DERIVATI 2-ARIL-6-FENILIMIDAZO[1,2-a]PIRIDINA, NJIHOVO DOBIVANJE I UPOTREBA U TERAPIJI |
Country Status (44)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2928924B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique |
| FR2928923B1 (fr) | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques |
| FR2928922B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique |
| FR2928921B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines, leur preparation et leur application en therapeutique |
| FR2933609B1 (fr) * | 2008-07-10 | 2010-08-27 | Fournier Lab Sa | Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson. |
| FR2950344B1 (fr) * | 2009-09-18 | 2011-11-25 | Sanofi Aventis | Derives de 5-phenyl-pyrazolopyridine, leur preparation et leur aplication en therapeutique. |
| FR2950345B1 (fr) * | 2009-09-18 | 2011-09-23 | Sanofi Aventis | Derives acetyleniques de 5-phenyl-pyrazolopyridine, leur preparation et leur application en therapeutique |
| FR2953520B1 (fr) * | 2009-12-04 | 2011-11-25 | Sanofi Aventis | Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique |
| CN104822679B (zh) * | 2012-11-29 | 2016-10-19 | 霍夫曼-拉罗奇有限公司 | 咪唑并吡啶衍生物 |
| TWI644899B (zh) | 2013-02-04 | 2018-12-21 | 健生藥品公司 | Ｆｌａｐ調節劑 |
| EP3070085B1 (en) | 2013-02-04 | 2019-01-09 | Janssen Pharmaceutica NV | Flap modulators |
| ES2883565T3 (es) * | 2013-08-02 | 2021-12-09 | Pasteur Institut Korea | Compuestos antiinfecciosos |
| EP3280715B1 (en) | 2015-04-10 | 2020-11-25 | Beigene, Ltd. | NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES |
| TW201718581A (zh) | 2015-10-19 | 2017-06-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| LT3377488T (lt) | 2015-11-19 | 2023-01-10 | Incyte Corporation | Heterocikliniai junginiai, kaip imunomoduliatoriai |
| SI3394033T1 (sl) | 2015-12-22 | 2021-03-31 | Incyte Corporation | Heterociklične spojine kot imunomodulatorji |
| MA44860A (fr) | 2016-05-06 | 2019-03-13 | Incyte Holdings Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| WO2017205464A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP4137489A1 (en) | 2016-06-20 | 2023-02-22 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018013789A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP3504198B1 (en) | 2016-08-29 | 2023-01-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP3515914A4 (en) * | 2016-09-24 | 2020-04-15 | BeiGene, Ltd. | NEW IMIDAZO [1,5-A] PYRIDINES SUBSTITUTED IN POSITION 5 OR 8 AS INDOLEAMINE AND / OR TRYPTOPHANE 2,3-DIOXYGENASES |
| MX2019007416A (es) | 2016-12-22 | 2019-12-11 | Incyte Corp | Derivados de benzooxazol como inmunomoduladores. |
| TWI798192B (zh) | 2016-12-22 | 2023-04-11 | 美商英塞特公司 | 免疫調節劑化合物及使用方法 |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| US20180179179A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2019101188A1 (en) | 2017-11-25 | 2019-05-31 | Beigene, Ltd. | Novel benzoimidazoles as selective inhibitors of indoleamine 2, 3-dioxygenases |
| ES2940750T3 (es) | 2018-03-30 | 2023-05-11 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| HRP20230306T1 (hr) | 2018-05-11 | 2023-05-12 | Incyte Corporation | Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori |
| CA3150434A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| TW202126652A (zh) | 2019-09-30 | 2021-07-16 | 美商英塞特公司 | 作為免疫調節劑之吡啶并［３，２—ｄ］嘧啶化合物 |
| KR20220101664A (ko) | 2019-11-11 | 2022-07-19 | 인사이트 코포레이션 | Pd-1/pd-l1 억제제의 염 및 결정질 형태 |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
| US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
| US11866434B2 (en) | 2020-11-06 | 2024-01-09 | Incyte Corporation | Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4041624B2 (ja) * | 1999-07-21 | 2008-01-30 | 三井化学株式会社 | 有機電界発光素子 |
| WO2001074813A2 (en) * | 2000-03-31 | 2001-10-11 | Ortho Mcneil Pharmaceutical, Inc. | METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS |
| GB0119911D0 (en) * | 2001-08-15 | 2001-10-10 | Novartis Ag | Organic Compounds |
| TWI351405B (en) * | 2002-09-19 | 2011-11-01 | Schering Corp | Novel imidazopyridines as cyclin dependent kinase |
| GB0303503D0 (en) * | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
| CN1930159A (zh) * | 2004-03-08 | 2007-03-14 | 北卡罗来纳大学查珀尔希尔分校 | 作为抗原生动物药的新的双阳离子咪唑并[1,2－a]吡啶和5,6,7,8－四氢－咪唑并[1,2－a]吡啶化合物 |
-
2006
- 2006-09-22 FR FR0608350A patent/FR2906250B1/fr active Active
-
2007
- 2007-09-13 TW TW096134253A patent/TWI381837B/zh not_active IP Right Cessation
- 2007-09-19 UA UAA200903928A patent/UA95976C2/ru unknown
- 2007-09-19 AR ARP070104136A patent/AR062897A1/es not_active Application Discontinuation
- 2007-09-19 MY MYPI20091157A patent/MY145603A/en unknown
- 2007-09-19 AU AU2007298856A patent/AU2007298856B2/en not_active Ceased
- 2007-09-19 CN CN2007800352403A patent/CN101516881B/zh not_active Expired - Fee Related
- 2007-09-19 NZ NZ575337A patent/NZ575337A/en not_active IP Right Cessation
- 2007-09-19 MX MX2009002802A patent/MX2009002802A/es active IP Right Grant
- 2007-09-19 PT PT07848251T patent/PT2069342E/pt unknown
- 2007-09-19 WO PCT/FR2007/001517 patent/WO2008034974A1/fr active Application Filing
- 2007-09-19 DK DK07848251.0T patent/DK2069342T3/da active
- 2007-09-19 BR BRPI0718517-0A patent/BRPI0718517A2/pt active Search and Examination
- 2007-09-19 PL PL07848251T patent/PL2069342T3/pl unknown
- 2007-09-19 ZA ZA200901551A patent/ZA200901551B/xx unknown
- 2007-09-19 DE DE602007006525T patent/DE602007006525D1/de active Active
- 2007-09-19 ES ES07848251T patent/ES2345016T3/es active Active
- 2007-09-19 EA EA200970311A patent/EA017442B1/ru not_active IP Right Cessation
- 2007-09-19 KR KR1020097005741A patent/KR101470039B1/ko not_active IP Right Cessation
- 2007-09-19 RS RSP-2010/0356A patent/RS51412B/en unknown
- 2007-09-19 ME MEP-107/09A patent/MEP10709A/xx unknown
- 2007-09-19 AT AT07848251T patent/ATE467633T1/de active
- 2007-09-19 CA CA2662848A patent/CA2662848C/fr not_active Expired - Fee Related
- 2007-09-19 SI SI200730316T patent/SI2069342T1/sl unknown
- 2007-09-19 EP EP07848251A patent/EP2069342B1/fr active Active
- 2007-09-19 JP JP2009528752A patent/JP5336378B2/ja not_active Expired - Fee Related
- 2007-09-20 JO JO2007401A patent/JO2643B1/en active
- 2007-09-20 PE PE2007001266A patent/PE20080671A1/es not_active Application Discontinuation
- 2007-09-21 UY UY30603A patent/UY30603A1/es not_active Application Discontinuation
- 2007-09-21 CL CL200702733A patent/CL2007002733A1/es unknown
-
2009
- 2009-02-26 CR CR10643A patent/CR10643A/es unknown
- 2009-03-02 IL IL197352A patent/IL197352A/en not_active IP Right Cessation
- 2009-03-05 GT GT200900049A patent/GT200900049A/es unknown
- 2009-03-10 TN TN2009000081A patent/TN2009000081A1/fr unknown
- 2009-03-18 HN HN2009000502A patent/HN2009000502A/es unknown
- 2009-03-19 US US12/407,449 patent/US7915284B2/en not_active Expired - Fee Related
- 2009-03-19 SV SV2009003193A patent/SV2009003193A/es active IP Right Grant
- 2009-03-19 NI NI200900037A patent/NI200900037A/es unknown
- 2009-03-19 CO CO09028759A patent/CO6160308A2/es unknown
- 2009-04-16 MA MA31788A patent/MA30792B1/fr unknown
- 2009-04-20 NO NO20091562A patent/NO20091562L/no not_active Application Discontinuation
-
2010
- 2010-02-22 HK HK10101842.6A patent/HK1135388A1/xx not_active IP Right Cessation
- 2010-07-20 CY CY20101100678T patent/CY1110232T1/el unknown
- 2010-07-23 HR HR20100408T patent/HRP20100408T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100408T1 (hr) | DERIVATI 2-ARIL-6-FENILIMIDAZO[1,2-a]PIRIDINA, NJIHOVO DOBIVANJE I UPOTREBA U TERAPIJI | |
| HRP20130029T1 (hr) | POLISUPSTITUIRANI DERIVATI 2-ARIL-6-FENILIMIDAZO[1,2-a]PIRIDINA, NJIHOVO DOBIVANJE I UPOTREBA U TERAPIJI | |
| JP6782756B2 (ja) | Ｋｉｔに関連する疾患を治療するために有用な化合物の製法と中間体化合物 | |
| Liverton et al. | Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase | |
| JP5738310B2 (ja) | ジフェニル−ピラゾロピリジン誘導体、この誘導体の調製および調節因子ではなく核受容体としてのこの誘導体の使用 | |
| US10533011B2 (en) | Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same | |
| JP2011515381A5 (es) | ||
| HRP20151077T1 (hr) | Derivati pirazola | |
| Viswambharan et al. | Synthesis and catalytic properties of 4-aryl-2, 3-dihydro-4 H-pyrimido [2, 3-b] benzothiazoles for asymmetric acyl or carboxyl group transfer reactions | |
| AR051919A1 (es) | Compuesto derivado de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimientos para preparar el compuesto | |
| JP2021536471A (ja) | メチル６−（２，４−ジクロロフェニル）−５−［４−［（３ｓ）−１−（３−フルオロプロピル）ピロリジン−３−イル］オキシフェニル］−８，９−ジヒドロ−７ｈ−ベンゾ［７］アンヌレン−２−カルボキシレートの塩およびその製造方法 | |
| NZ588084A (en) | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | |
| HRP20110015T1 (hr) | DERIVATI IMIDAZO[1,2-a]PIRIDIN-2-KARBOKSAMIDA, NJIHOVO DOBIVANJE I NJIHOVA UPOTREBA U TERAPIJI | |
| JP2011515382A (ja) | 多置換２−アリール−６−フェニル−イミダゾ［１，２−ａ］ピリジン誘導体、ならびにこれらの調製および治療的使用 | |
| NZ630467A (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| US7772248B2 (en) | Preparation and utility of substituted imidazopyridine compounds with hypnotic effects | |
| JPWO2021155468A5 (es) | ||
| Mesaros et al. | Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo [2, 1-f][1, 2, 4] triazines: identification of orally bioavailable, efficacious ALK inhibitors | |
| ES2912264T3 (es) | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de PDE2 | |
| RU2010119560A (ru) | Замещенные n-фенилбипирролидинкарбоксамиды и их терапевтическое применение | |
| JP2007529495A5 (es) | ||
| HRP20151282T1 (hr) | Heterocikliäśki spojevi za lijeäśenje ili prevenciju bolesti izazvanih smanjenom neurotransmisijom serotonina, norepinefrina ili dopamina | |
| Wang et al. | Synthesis of chromeno [2, 3-d] pyrimidin-5-one derivatives from 1, 3, 5-triazinanes via two different reaction pathways | |
| Duquette et al. | Probing trends in enantioinduction via substrate design: Palladium-catalyzed decarboxylative allylic alkylation of α-enaminones | |
| HRP20141119T1 (hr) | Derivati 5-fenilpirazolopiridina, njihovo dobivanje i njihova upotreba u terapiji |